



Drug Coverage Decision for BC PharmaCare

About PharmaCare

BC PharmaCare is a publicly funded drug plan that helps B.C. residents pay for most prescription drugs and pharmacy services, and some medical devices and supplies.

Details of Drug Reviewed

Drug	atogepant
Brand name	Qulipta®
Dosage form(s)	10 mg, 30 mg, and 60 mg tablets
Manufacturer	AbbVie Corporation
Submission type	New Submission
Indication reviewed	For the prevention of episodic and chronic migraine in adults
Canada's Drug Agency (CDA-AMC) Clinical Reimbursement Reviews (CRR)	CDA-AMC recommended: to Reimburse with clinical criteria and/or conditions. Visit the CRR website for more details .
Drug Benefit Council (DBC)	The DBC now screens drug submissions under review by CRR to determine whether or not a full DBC review is necessary, based on past DBC reviews, recommendations, and existing PharmaCare coverage. If a full DBC review is determined to not be required, the Ministry's drug coverage decision will be based on the Canadian Drug Expert Committee (CDEC) recommendation and an internal review only. The DBC screened atogepant. Since atogepant is similar to other drugs that were previously reviewed by DBC for the prevention of episodic and chronic migraine in adults, the Ministry may accept the CDEC's recommendation for atogepant.
Drug Coverage Decision	Limited Coverage benefit. Access the atogepant criteria from: http://www.gov.bc.ca/pharmacarespecialauthority

Date	December 3, 2024
Reason(s)	<p>Drug coverage decision is consistent with the CDEC recommendation.</p> <ul style="list-style-type: none">• Based on CRR reviews, atogepant reduced the frequency of migraines compared to placebo based on the change from baseline in the number of monthly migraine days (MMD) from weeks 1 to 12. Atogepant also reduced migraine symptoms in patients, and the use of atogepant was well-tolerated.• Based on CRR assessment of the health economic evidence, atogepant does not represent good value to the health care system at the public list price, and there is not enough robust evidence to justify a greater cost for atogepant compared with relevant anti-calcitonin gene-related peptide (anti-CGRP) comparators reimbursed for the prevention of episodic or chronic migraine.• The Ministry participated in the pan-Canadian Pharmaceutical Alliance negotiations with the manufacturer which were able to address the concerns identified by the CDEC with respect to the cost-effectiveness and value for money.

The drug review process in B.C.

A manufacturer submits a request to the Ministry of Health (the Ministry).

An independent group called the [Drug Benefit Council \(DBC\)](#) gives advice to the Ministry by considering:

- whether the drug is safe and effective
- advice from a national group called [Canada's Drug and Health Technology Agency \(CADTH\)](#)
- what the drug costs and whether funding it provides good value to the province
- ethical considerations of covering and not covering the drug
- input from physicians, patients, caregivers, patient groups and drug submission sponsors

The Ministry makes a BC PharmaCare coverage decision by taking into account:

- existing BC PharmaCare policies, programs and resources
- the evidence-informed advice of the DBC
- drugs already covered by BC PharmaCare that treat similar medical conditions
- the overall cost of covering the drug

Visit [BC PharmaCare](#) and [Drug reviews](#) for more information.

This document is intended for information only.

It does not take the place of advice from a physician or other qualified health care provider.